Wutah pendapatan taunan sajrone rolas wulan kepungkur: Burning Rock Biotech Ltd (BNR)

Logo grafis Burning Rock Biotech (BNR)

Burning Rock Biotech (BNR) faces regulatory risks in the PRC despite the high transparency of audits. The trailing twelve months (TTM) annual growth in operating sales revenue reflects revenue dynamics, where the -3.60 mark characterizes this parameter. Patent protection and access to biodata strengthen the company's position, yet government pressure on the cost of medical services forces the business to provide significant discounts to clinics.

BNR (Burning Rock) riwayat Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Ringkesan rincian data analitis Burning Rock Biotech Ltd. (BNR)

- nilai saham lan prakiraan konsensus rega:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:BNR Burning Rock Biotech Ltd
Produk merek Burning Rock Biotech Limited

This indicator measures the dynamics of total revenue over a rolling twelve-month period relative to the previous year. For Burning Rock Biotech (BNR), this metric reveals the impact of geopolitical restrictions on biotechnology exports and data exchange. By analyzing the annual sales growth rate over a 12-month window, an investor distinguishes random spikes from a systemic trend. A decline in growth rates signals a risk of business stagnation, while a stable trajectory confirms capital resilience.